Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.
Gerbasi, Margaret E; Stellato, Daniel; Ghate, Sameer R; Ndife, Briana; Moynahan, Aaron; Mishra, Dinesh; Gunda, Praveen; Koruth, Roy; Delea, Thomas E.
J Med Econ
; 22(12): 1243-1252, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31223037
Cost-effectiveness analysis of patient self-testing therapy of oral anticoagulation.
A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting.
Cost-effectiveness of comprehensive geriatric assessment at an ambulatory geriatric unit based on the AGe-FIT trial.
Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemiaã- An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.
Cost-effectiveness of pelvic exenteration for locally advanced malignancy.
Cost-effectiveness of population-based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial.
Similar cost-utility for double- and single-bundle techniques in ACL reconstruction.
Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.